Gentaro Ikeda1, Michelle R Santoso2, Yuko Tada3, Albert M Li4, Evgeniya Vaskova3, Ji-Hye Jung3, Connor O'Brien3, Elizabeth Egan5, Jiangbin Ye4, Phillip C Yang6. 1. Stanford Cardiovascular Institute and Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. Electronic address: https://twitter.com/gentaro_ikeda. 2. Stanford Cardiovascular Institute and Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. Electronic address: https://twitter.com/meeshsantoso. 3. Stanford Cardiovascular Institute and Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 4. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA. 5. Division of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA. 6. Stanford Cardiovascular Institute and Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. Electronic address: phillip@stanford.edu.
Abstract
BACKGROUND: Mitochondrial dysfunction results in an imbalance between energy supply and demand in a failing heart. An innovative therapy that targets the intracellular bioenergetics directly through mitochondria transfer may be necessary. OBJECTIVES: The purpose of this study was to establish a preclinical proof-of-concept that extracellular vesicle (EV)-mediated transfer of autologous mitochondria and their related energy source enhance cardiac function through restoration of myocardial bioenergetics. METHODS: Human-induced pluripotent stem cell-derived cardiomyocytes (iCMs) were employed. iCM-conditioned medium was ultracentrifuged to collect mitochondria-rich EVs (M-EVs). Therapeutic effects of M-EVs were investigated using in vivo murine myocardial infarction (MI) model. RESULTS: Electron microscopy revealed healthy-shaped mitochondria inside M-EVs. Confocal microscopy showed that M-EV-derived mitochondria were transferred into the recipient iCMs and fused with their endogenous mitochondrial networks. Treatment with 1.0 × 108/ml M-EVs significantly restored the intracellular adenosine triphosphate production and improved contractile profiles of hypoxia-injured iCMs as early as 3 h after treatment. In contrast, isolated mitochondria that contained 300× more mitochondrial proteins than 1.0 × 108/ml M-EVs showed no effect after 24 h. M-EVs contained mitochondrial biogenesis-related messenger ribonucleic acids, including proliferator-activated receptor γ coactivator-1α, which on transfer activated mitochondrial biogenesis in the recipient iCMs at 24 h after treatment. Finally, intramyocardial injection of 1.0 × 108 M-EVs demonstrated significantly improved post-MI cardiac function through restoration of bioenergetics and mitochondrial biogenesis. CONCLUSIONS: M-EVs facilitated immediate transfer of their mitochondrial and nonmitochondrial cargos, contributing to improved intracellular energetics in vitro. Intramyocardial injection of M-EVs enhanced post-MI cardiac function in vivo. This therapy can be developed as a novel, precision therapeutic for mitochondria-related diseases including heart failure.
BACKGROUND: Mitochondrial dysfunction results in an imbalance between energy supply and demand in a failing heart. An innovative therapy that targets the intracellular bioenergetics directly through mitochondria transfer may be necessary. OBJECTIVES: The purpose of this study was to establish a preclinical proof-of-concept that extracellular vesicle (EV)-mediated transfer of autologous mitochondria and their related energy source enhance cardiac function through restoration of myocardial bioenergetics. METHODS: Human-induced pluripotent stem cell-derived cardiomyocytes (iCMs) were employed. iCM-conditioned medium was ultracentrifuged to collect mitochondria-rich EVs (M-EVs). Therapeutic effects of M-EVs were investigated using in vivo murine myocardial infarction (MI) model. RESULTS: Electron microscopy revealed healthy-shaped mitochondria inside M-EVs. Confocal microscopy showed that M-EV-derived mitochondria were transferred into the recipient iCMs and fused with their endogenous mitochondrial networks. Treatment with 1.0 × 108/ml M-EVs significantly restored the intracellular adenosine triphosphate production and improved contractile profiles of hypoxia-injured iCMs as early as 3 h after treatment. In contrast, isolated mitochondria that contained 300× more mitochondrial proteins than 1.0 × 108/ml M-EVs showed no effect after 24 h. M-EVs contained mitochondrial biogenesis-related messenger ribonucleic acids, including proliferator-activated receptor γ coactivator-1α, which on transfer activated mitochondrial biogenesis in the recipient iCMs at 24 h after treatment. Finally, intramyocardial injection of 1.0 × 108 M-EVs demonstrated significantly improved post-MI cardiac function through restoration of bioenergetics and mitochondrial biogenesis. CONCLUSIONS: M-EVs facilitated immediate transfer of their mitochondrial and nonmitochondrial cargos, contributing to improved intracellular energetics in vitro. Intramyocardial injection of M-EVs enhanced post-MI cardiac function in vivo. This therapy can be developed as a novel, precision therapeutic for mitochondria-related diseases including heart failure.
Authors: Aditya K Kaza; Isaac Wamala; Ingeborg Friehs; Joseph D Kuebler; Rahul H Rathod; Ignacio Berra; Maria Ericsson; Rouan Yao; Jerusha K Thedsanamoorthy; David Zurakowski; Sidney Levitsky; Pedro J Del Nido; Douglas B Cowan; James D McCully Journal: J Thorac Cardiovasc Surg Date: 2016-11-15 Impact factor: 5.209
Authors: Geoffrey de Couto; Romain Gallet; Linda Cambier; Ervin Jaghatspanyan; Nupur Makkar; James Frederick Dawkins; Benjamin P Berman; Eduardo Marbán Journal: Circulation Date: 2017-04-14 Impact factor: 29.690
Authors: Ljubava D Zorova; Sergei I Kovalchuk; Vasily A Popkov; Valery P Chernikov; Anastasia A Zharikova; Anastasia A Khutornenko; Savva D Zorov; Konstantin S Plokhikh; Roman A Zinovkin; Ekaterina A Evtushenko; Valentina A Babenko; Irina B Pevzner; Yulia A Shevtsova; Kirill V Goryunov; Egor Y Plotnikov; Denis N Silachev; Gennady T Sukhikh; Dmitry B Zorov Journal: Int J Mol Sci Date: 2022-07-03 Impact factor: 6.208
Authors: Connor G O'Brien; Mehmet Ozgun Ozen; Gentaro Ikeda; Evgeniya Vaskova; Ji Hye Jung; Nathan Bayardo; Michelle Rai Santoso; Liye Shi; Christine Wahlquist; Zewen Jiang; Yunshin Jung; Yitian Zeng; Elizabeth Egan; Robert Sinclair; Adrian Gee; Ronald Witteles; Mark Mercola; Katrin J Svensson; Utkan Demirci; Phillip C Yang Journal: JACC CardioOncol Date: 2021-07-27